Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: Evidence for in situ T-cell activation and therapeutic efficacy

International Journal of Cancer

Volumn 91, Issue 2, 2001, Pages 225-230

  Jung, Gundram ^a,c   Brandl, Martina ^a   Eisner, Wilhelm ^a   Fraunberger, Peter ^a   Reifenberger, Guido ^b   Schlegel, Uwe ^a   Wiestler, Otmar D ^a   Reulen, Hans Jrgen ^b   Wilmanns, Wolfgang ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bispecific antibodies; CD28; CD3; Glioma; Immunotherapy

Indexed keywords

BIOCHEMICAL MARKER; BISPECIFIC ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 2 RECEPTOR; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ADULT; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; BRAIN EDEMA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FEVER; GLIOBLASTOMA; HEADACHE; HUMAN; HUMAN CELL; MALE; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; VOMITING;

EID: 0035863587     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1038>3.3.CO;2-7     Document Type: Article

References (28)

1. Hybrid antibodies can target sites for attack by T cells
2. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target antibody
3. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes
4. T-cell based cancer immunotherapy: Direct or indirect tumor cell recognition?
5. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype X anti-CD3)
6. Bispecific anti-idiotype/anti-CD3 therapy of murine B cell lymphoma
7. Tumor growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T cell costimulation via CD28
8. Reduction of EGP-2 positive pulmonary metastasis by bispecific antibody redirected T cells in an immunocompetent rat model
9. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody
10. Preliminary trial of specific targeting therapy against malignant glioma
11. Target cell induced T cell activation with bi- and trispecific antibody fragments
12. Cytolysis of leukemic B cells by T cells activated via two bispecific antibodies
13. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
14. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
15. Can co-stimulated tumor immunity be therapeutically efficious?
16. Co-stimuation in T cell responses
17. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies
18. Role of target antigen in bispecific antibody mediated killing of human glioblastoma cells: A preclinical study
19. Epidermal growth factor receptor expression in human malignant glioma: In vitro and in vivo effects of application of monoclonal antibodies to the epidermal growth factor receptor
20. Removal of endotoxin from protein solutions by separation using Triton X-114
21. 2 bispecific monoclonal antibody
22. Long term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy
23. Improved long term survival after intracavitary interleukin-2 and lymphokine activated killer cells for adults with recurrent malignant glioma
24. Treatment of recurrent gliomas with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2
25. Phase I study of intravenously applied bispecific antibodies in renal cell cancer patients receiving subcutaneous interleukin-2
26. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody Oc/TR Fab2 in ovarian carcinoma patients
27. Myeloablative chemotherapy, stem cell transplantation, T-cell reinfusion and redirecting bispecific antibodies in patients with metastatic breast cancer: A phase I trial
28. Bispecific antibody fragments with CD20 × CD28-specificity allow effective autologous and allogeneic T cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma